R

Regeneron Pharmaceuticals

Develops biopharmaceutical therapies for serious diseases

Senior Financial Analyst - SOX Compliance

Full-TimeUpdated on 10/24/2026
$83.8k - $136.8k/yr
Senior
Bachelor's, MBA
Warren, NJ, USA+1 moreMore locations: Sleepy Hollow, NY, USA
HybridOn-site four days per week at either the Sleepy Hollow, NY or Warren, NJ office.
Risk & ComplianceInternal Audit & Controls

About the job

Requirements
  • A bachelor's degree in Finance, Accounting, or a related quantitative field is required.
  • At least five years of experience in compliance, forecasting, budgeting, and/or business partnering is required.
  • A proven track record spanning both audit and finance functions is required.
Responsibilities
  • Ensure financial controls are executed in line with the company's SOX requirements.
  • Partner with the Head of Program Finance to present process changes to the SOX Committee and keep SOX documentation (narratives) current.
  • Lead the annual SOX audit process by running walkthroughs with internal and external auditors and preparing documentation for Study Budget and Study Requisition approvals as part of key controls testing.
  • Advise Program Finance and Global Development teams on SOX key controls for Study Budget and Study Requisition approvals.
  • Conduct ad-hoc reviews of Program Trial Finance analysts' documentation, identify gaps or weaknesses, and recommend improvements to strengthen controls.
  • Champion operational improvements that reduce unnecessary work and streamline processes within SOX guardrails.
  • Submit and update approved budget information in Hyperion.
  • Review budget dashboards to confirm accurate reporting of approved budgets.
  • Review custom hierarchies for clinical trials and required approvers.
  • Administer and maintain study budget approval workflows and QlikView dashboards that support SOX compliance, partnering with IT support teams.
  • Periodically review budget values in Hyperion to keep QlikView budget dashboards accurate and up to date.
Desired Qualifications
  • Experience in a science- or research-driven organization is preferred.
  • An MBA is a plus.

About the company

R

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
  • Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
  • Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.

What critics are saying

  • EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
  • Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
  • Dupixent's patent cliff later this decade threatens the company's biggest profit pool.

What makes Regeneron Pharmaceuticals unique

  • VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
  • Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
  • EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Wellness Program
  • Paid Vacation
  • Equity Awards
  • Annual Bonuses
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

1%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 28th, 2026
Regeneron shares return 25.3% in a year, but is the $816 price too high?

Regeneron Pharmaceuticals shareholders earned a 25.3% return over the past year, including dividends. The shares now trade at $816, up from $585 at the start of the period. A bullish view put fair value at $722, assuming 5.4% annual revenue growth and a 30.1% profit margin. A cautious view put it at $540, citing margin strain from US healthcare reforms and biosimilars. The evidence cut both ways. Regeneron signed multibillion-dollar collaborations in radiopharmaceuticals and Helicon peptides, and expanded its work with Sanofi. But second-quarter net margin fell from 37.9% to 30.2%, with revenue at $4,290.7 million. At $816, the price assumes pipeline assets will offset pricing pressure and competition. Risks include heavy reliance on EYLEA and Dupixent, trial uncertainty, and lawsuits.

Yahoo Finance
Oct 27th, 2026
Regeneron pivots as EYLEA HD overtakes EYLEA, with Q2 revenue up 16.7%

Regeneron Pharmaceuticals has changed its message on its eye drugs. On its July 30, 2026 call, management said the newer EYLEA HD had outsold EYLEA for the first time. In February 2025, it focused on keeping EYLEA's market share. In the second quarter of 2026, US sales of EYLEA HD rose 52% from a year earlier, while EYLEA's fell 45%. EYLEA HD now makes up about 60% of US sales for the two drugs, against 34% a year earlier. Total revenue rose 16.7%, helped by higher Sanofi collaboration revenue, EYLEA HD and Libtayo. Management expects EYLEA demand to fall by a low to mid-teens percentage each quarter in the second half, partly due to biosimilars. The stock trades at 19.2 times earnings, against 22.9 for the S&P 500.

Yahoo Finance
Oct 26th, 2026
Regeneron to book full Dupixent profit share in Q3 after $930M repayment drag

Regeneron reports third-quarter results on October 30, and it will book its full share of Dupixent profits from Sanofi for the first time. Repayments of a development balance, which stood at about $3.1 billion in 2022, cut collaboration revenue by roughly $930 million in 2025. Last quarter, Regeneron posted non-GAAP earnings per share of $14.29 against an $8.00 consensus. Revenue rose 16.73% to $4.29 billion, and global Dupixent sales reached $6.00 billion, up 38%. The companies also expanded their alliance to up to $8 billion, adding four long-acting antibodies and settling prior litigation. Eylea HD US sales hit $596 million, up 52%, passing legacy Eylea for the first time. Analysts expect third-quarter revenue of $4.56 billion.

Yahoo Finance
Oct 21st, 2026
Regeneron trades at 19.2x earnings versus Amgen's 27.1x despite similar growth

Regeneron Pharmaceuticals trades at 19.2 times earnings for the four quarters ended June 30, 2026, well below Amgen's 27.1, though both grew revenue at a similar pace. Regeneron's revenue rose 9.3% against Amgen's 9.1%. Amgen has the higher operating margin, at 30.0% against 26.9%. Its shares also gained more over the past year, rising 51.0% against 40.4%. Regeneron's largest drug, EYLEA, is shrinking. Its revenue fell to $2.75 billion in fiscal 2025 from $4.77 billion, and management expects demand to fall further as biosimilars launch. Partners supply about half of revenue, and management expects Sanofi collaboration revenue to rise from fiscal Q3 2026. The next report is expected on or around October 30, 2026.

Yahoo Finance
Oct 19th, 2026
Regeneron's weight loss drugs could challenge Eli Lilly and Novo with 19% weight loss

Regeneron Pharmaceuticals could carve out a place in the fast-growing weight loss market, where Eli Lilly and Novo are expected to stay ahead for about five years. Its drug olatorepatide, licensed from a China-based company, mimics the GLP-1 and GIP hormones, as Lilly's Zepbound does. In a Phase 3 study in China, it led to mean weight loss of up to 19% over 48 weeks, with fewer stomach-related side effects than some rivals. Regeneron still needs US late-stage trials before approval. Its other candidate, trevogrumab, helps patients keep lean mass. In a Phase 2 study alongside Novo's semaglutide, lean mass preservation reached up to 42.5%, against 7.3% with semaglutide plus placebo. Second-quarter revenue rose 17% year over year to $4.3 billion, driven by eczema drug Dupixent.